Infectious bursal disease virus (IBDV) is the etiological agent of IB, which affects lymphoid tissue of the cloacal bursa of young chickens and causes severe immune suppression with high mortality [1]. There are two serotypes of IBDV, and only serotype 1 viruses are virulent to chickens. Serotype 1 viruses can be further divided into different pathotypes according to their pathogenicity, namely the classic form of virulent IBDV (cvIBDV), antigenic variant strains (avIBDV), and very virulent strains (vvIBDV) [2]. Since 1990s, vvIBDV has become the dominant pathotype with increasing number of isolates obtained even from the vaccinated chicken flocks and caused huge amount of economic losses in China [3].

IBDV belongs to the genus *Avibirnavirus* of the family *Birnaviridae*. The genome of virus consists of two double-stranded RNA segments. Five viral proteins (VP1-VP5) have so far been identified. Among them, VP2 is the major host-protective antigen and anti-IBDV antibody induced by recombinant VP2 could protect chickens against virus infection [4]. Therefore, VP2 protein was previously expressed in prokaryocyte such as *E. coli* and eukaryotes such as yeast and baculovirus to work as subunit vaccines [4-6].

Compared to eukaryotes, prokaryocyte *E. coli* has several advantages over eukaryote expression system since it could be easily handled and is less expensive. However, several studies reported the VP2 expression products in *E. coli* were insoluble and useless in production of subunit vaccines against IBDV [7,8]. One study has successfully expressed the soluble recombinant VP2 protein in *E. coli* bacteria and the crude products were used directly on chickens [9]. Although results of the study showed crude subunit vaccines could provide protection against IBDV, biosafety concerns such as bacteria components and antibiotic gene in vaccines will jeopardize food consumers when they consume the chickens vaccinated with above vaccines. Also, pre-exist antibodies against *E. coli* in chickens will deteriorate the efficacy of vaccination if the recombinant vaccines contain bacterial components. Therefore, in this study, we expressed soluble recombinant VP2 protein in *E. coli* and removed the bacteria components by ion-exchange chromatography. The purified recombinant VP2 protein was then evaluated the efficacy on chickens as a subunit candidate to be used on chickens.

**Abbreviations**
- IBDV: Infectious Bursal Disease Virus; DPV: Days Post-Vaccination; AGP: Agar Gel diffusion Precipitation;
- **Introduction**

Infectious bursal disease virus (IBDV) is the etiological agent of IB, which affects lymphoid tissue of the cloacal bursa of young chickens and causes severe immune suppression with high mortality [1]. There are two serotypes of IBDV, and only serotype 1 viruses are virulent to chickens. Serotype 1 viruses can be further divided into different pathotypes according to their pathogenicity, namely the classic form of virulent IBDV (cvIBDV), antigenic variant strains (avIBDV), and very virulent strains (vvIBDV) [2]. Since 1990s, vvIBDV has become the dominant pathotype with increasing number of isolates obtained even from the vaccinated chicken flocks and caused huge amount of economic losses in China [3].

IBDV belongs to the genus *Avibirnavirus* of the family *Birnaviridae*. The genome of virus consists of two double-stranded RNA segments. Five viral proteins (VP1-VP5) have so far been identified. Among them, VP2 is the major host-protective antigen and anti-IBDV antibody induced by recombinant VP2 could protect chickens against virus infection [4]. Therefore, VP2 protein was previously expressed in prokaryocyte such as *E. coli* and eukaryotes such as yeast and baculovirus to work as subunit vaccines [4-6].

Compared to eukaryotes, prokaryocyte *E. coli* has several advantages over eukaryote expression system since it could be easily handled and is less expensive. However, several studies reported the VP2 expression products in *E. coli* were insoluble and useless in production of subunit vaccines against IBDV [7,8]. One study has successfully expressed the soluble recombinant VP2 protein in *E. coli* bacteria and the crude products were used directly on chickens [9]. Although results of the study showed crude subunit vaccines could provide protection against IBDV, biosafety concerns such as bacteria components and antibiotic gene in vaccines will jeopardize food consumers when they consume the chickens vaccinated with above vaccines. Also, pre-exist antibodies against *E. coli* in chickens will deteriorate the efficacy of vaccination if the recombinant vaccines contain bacterial components. Therefore, in this study, we expressed soluble recombinant VP2 protein in *E. coli* and removed the bacteria components by ion-exchange chromatography. The purified recombinant VP2 protein was then evaluated the efficacy on chickens as a subunit candidate to be used on chickens. **Materials and Methods**

**Virus**

vvIBDV strain HuB was isolated from a poultry farm in Hubei province in China and was used for final challenge study. Briefly,
bursae of sick chickens were collected and homogenised in PBS (1:10 ratio). The ELD_{50} was performed on chicken embryo and the titer was 10^{6.5} ELD_{50} per 0.2ml after Reed-Muench calculation. For virus challenge, 0.2ml of a 1/2 dilution in PBS of a bursal homogenate of vvIBDV strain was used [10]. The final challenge titer for one chicken was 1x10^{6.5} ELD_{50}/0.2ml.

Preparation of recombinant protein

The code optimized full-length of VP2 gene (1356 bp) was synthesized and inserted into the expression plasmid pET32a (Supplementary Figure 1). IPTG was used to induce the expression of recombinant protein with a final concentration of 0.4mM at 28 °C for 4 hours. Cells were harvested and were broken by sonication. The supernatant containing soluble recombinant VP2 proteins were purified by ion-exchange chromatography to remove cell proteins. Briefly, Q Sepharose Fast Flow was packed in an XK26/20 column (2.5 ml) and was equilibrated by three column volumes of 50 mM Tris-HCl (pH8.0). The resuspended protein solution was loaded into the column. The column was washed by four column volumes of 50 mM Tris-HCl (pH8.0) and the protein was eluted by 0.5 M NaCl with 50 mM Tris-HCl (pH8.0). The crude and purified proteins were subjected to SDS-PAGE and western-blot. A polyclonal anti-IBDV antibody was used to test the specificity of recombinant protein in western-blotting.

Animal trial

Forty 21-day old chickens were randomly divided into four groups. Recombinant VP2 protein at 1:16 AGP antigen titer was mixed with commercial Marcel 52 oil (ExxonMobil, France) emulsion at 1:2 (v/v) to make water-in-oil emulsion vaccine. Chickens in group VP2 were intramuscularly injected with recombinant VP2 vaccine at a dose of 0.2 ml per chicken. Chickens in group B87 received one dose of commercial live vaccines of IBDV B87 strain (HLJ Animal-use Biological Products Co., Ltd., China). Chickens in groups CC and NC received placebo PBS. After 21 days post-vaccination (dpv), chickens in first three groups were challenge with vvIBDV HuB. Chickens in group NC were not received viral challenge and worked as sterile control throughout the study. After 10 days post-challenge, the survived chickens were euthanized. Bursa of fabricius were weighed and the ratio of bursa of Fabricius (BF) and body weight (BW) was calculated using the formula: (BF weight (in g)/BW (in g)) ×1000. The levels of protection were evaluated based on the mortality and histopathological bursal lesions as previously described [11]. The animal trial in this study was approved by the Animal Care and Ethics Committee of China National Research Center for Veterinary Medicine, and conventional animal welfare regulations and standards were taken into account.

Statistical analysis

All data were expressed as mean ± SD and were analyzed by one-way ANOVA followed by post-hoc Tukey’s test in Graph Pad Prism5.0 Software (San Diego, CA). P values of less 0.05 were considered significant.

Results

Expression of recombinant of VP2 protein

After induced by IPTG in E.coli BL21DE3 at 28 °C for 4 hours, cells were disrupted by sonication. The recombinant VP2 protein was found in the supernatant of cell lysis by SDS-PAGE result (Figure 1A). The MW of recombinant VP2 protein in this study is 37kd, which is consistent with one early report [9], but lower than 52 kd reported by Yu [8]. After purification by ion-exchange chromatography, the purified protein was subjected to western blot. The recombinant protein reacted specifically with IBDV VP2 antibody as shown by Figure 1B.

AGP-antibody response after vaccination

Every 7 days post-vaccination, IBDV-specific antibodies were monitored by AGP. As shown by Table 1, antibodies could be detected at 14dpv, and all chickens vaccinated with recombinant VP2 subunit vaccine developed positive antibodies. As compared with subunit vaccine, 8 out 10 chickens vaccinated with commercial vaccines showed positive antibodies. At 21 dpv, all chickens in vaccinated groups showed positive antibody response. Chickens in CC and NC groups did not show IBDV-specific antibody immune response as expected.

Protection after vvIBDV challenge

After challenge, typical clinical signs of IBD including anorexia and ruffled feathers began to appear in CC group. Chickens in this group died at 3-6 dpc with 60% mortality. No clinical signs were observed in other three groups. At necropsy, bursa of fabricius of chickens in CC groups showed severe hemorrhages, lymphoph necrosis, and lymphocyte depletion during histopathological examination. Several chickens vaccinated with B87 showed slight fibroplasias in the inter follicular connective tissues and infiltration of recticular epithelial cells. No hemorrhages or necrosis were observed. By contrast, the integrity of bursal follicles of VP2-vaccinated chickens was similar to the chickens in NC group and no hemorrhages or necrosis was observed. The histopathological bursal follicle lesion scores were summarized in Table 2. Therefore, the above results showed that recombinant VP2 subunit vaccine could provide complete protection to the vvIBDV HuB challenge.

Discussion

vvIBDV has become the predominant pathotype and led to...
This study could elicit higher titer of AGP antibodies (Table 1). Protein after renaturation of inclusion body protein. VP2 protein in previous study could be due to the incorrect folding of neutralizing epitopes [14]. The inefficacy of insoluble recombinant protein biological properties since VP2 contains at least three independent epitopes responsible for the induction of protective immunity which confers good protection to the field virus reinfection [4].

Several studies reported the failure of expressing VP2 protein in E.coli [4]. The chicken study results showed that the recombinant VP2-based subunit vaccines induce both viral neutralizing antibodies and cellular immunity which confers good protection to the field virus reinfection [4].

As compared with commercial live vaccines, VP2 subunit vaccine in this study did not lead to bursal atrophy but provide 100% protection [9], which indicates the subunit vaccine in this study could be a decent vaccine candidate to control infection. Therefore, the vaccinated chickens were challenged with a vvIBDV strain on 21 days-post vaccination. The challenge results showed that VP2 subunit vaccine could provide better protection than commercial live vaccines based on clinical manifestations and histopathological examinations. Moreover, VP2 subunit vaccine in this study did not lead to bursal atrophy but provide 100% protection to the vvIBDV HuB strain challenge.

| Table 1: AGP antibody titer (log GM±SD) after vaccination. |
|-------------------|-------------------|-------------------|-------------------|
| Group | 7 dpv | 14dpv | 21dpv |
| VP2 | ud† (0/10) | 3.9±0.9† (10/10) | 5.3±1.1 (10/10) |
| B87 | ud (0/10) | 2.7±1.3 (8/10) | 4.9±1.2 (10/10) |
| CC | ud (0/10) | ud (0/10) | ud (0/10) |
| NC | ud (0/10) | ud (0/10) | ud (0/10) |

Note: †AGP antibody titer was expressed as log₂GM±SD, GMT-geometric mean titer. **Ratio of AGP positive chickens/all chickens in one group.

| Table 2: Protection efficacy after vvIBDV HuB challenge. |
|-------------------|-------------------|-------------------|-------------------|
| Group | BF/BW ratio† | Bursal gross lesion score§ | Score 0 ratio | Protection (%) |
| VP2 | 1.12±0.37† | 9 | 0 1 2 3 4 5 | 9(10) | 100% |
| B87 | 0.84±0.22† | 2 | 0 1 2 3 4 5 | 2(10) | 60% |
| CC | 0.42±0.28å | 0 | 0 1 2 3 4 5 | 0(10) | 0% |
| NC | 1.39±0.48å | 10 | 0 1 2 3 4 5 | 10(10) | 100% |

Note: †Values followed by the same capital letter within the column do not differ significantly (P>0.05) as determined by one-way ANOVA. §Bursal gross lesions were scored from 0 to 5 based on the severity of bursal damage (0: no lesion, 1: slight change, 2: scattered or partial bursal damage, 3: 50% or less follicle damage, 4: 51%–75% follicle damage, 5: 76%–100% bursal damage). **Protection was defined by the number of chickens with histopathological BF lesion score (0 and 1) the number of chickens in the group. Percentage of AGP anti-IBDV antibodies and protection percentage of chickens after viral challenge [9], which indicates the subunit vaccine in this study could be a decent vaccine candidate to control infection. Therefore, the vaccinated chickens were challenged with a vvIBDV strain on 21 days-post vaccination. The challenge results showed that VP2 subunit vaccine could provide better protection than commercial live vaccines based on clinical manifestations and histopathological examinations. Moreover, VP2 subunit vaccine in this study did not lead to bursal atrophy but provide 100% protection to the vvIBDV HuB strain challenge.

### Conclusion

To conclude, we expressed and purified the recombinant IBDV VP2 protein in E.coli. The chicken study results showed that the recombinant VP2 protein could be used as a good subunit vaccine since it provided a complete protection to the challenge of a current circulating strain of IBDV.

### Acknowledgement

This work was supported by grant from Major Science and Technology Program in Henan Province (Grant No.131100110200) and Science and Technology Innovation team in Henan Province (Team No. C20130005).

### References


